Telich TJE, García TIV, Telich VJ, Villanueva SE

Language: Spanish
References: 26
Page: 190-193
PDF size: 160.87 Kb.

ABSTRACT

Introduction: chronic anal fissure is a linear split of the anoderm. Although surgery is the gold standard treatment, its side effects raise concerns. Recent studies have suggested encouraging results for the role of botulinum toxin in the treatment of anal fissures. This study aims to demonstrate the effectiveness of botulinum toxin type A for the treatment of anal fissures. Material and methods: fifteen patients with a diagnosis of anal fissures refractory to conservative management were included. 16 IU of toxin was applied to each patient and distributed in two sites on the 3 and 9 o'clock axes. They were subsequently evaluated in the outpatient clinic over two months. Results: 15 patients were treated, seven men (46%) and eight women (53%), with a median age of 39 years (range 22 to 72). Twelve patients (80%) presented a complete resolution of the condition. The rest of the patients underwent surgical procedures due to treatment failure. Conclusions: BT injection has been an accepted method for the management of CAF. This study demonstrates a cure rate of 80% with a 16 IU dose of botulinum toxin distributed along the 3 and 9 o'clock axes in the anal canal.

REFERENCES

1. Stewart DB Sr, Gaertner W, Glasgow S, Migaly J, Feingold D, Steele SR. Clinical Practice Guideline for the Management of Anal Fissures. Dis Colon Rectum. 2017; 60 (1): 7-14.

2. Montaño-Torres E, Cosme-Reyes C, Villanueva-Herrero JA, Alarcon-Bernes L, Salgado L, Jiménez-Bobadilla B. Diagnóstico y tratamiento de la fisura anal en el adulto. México: Secretaría de Salud. 2013.

3. Chiarello M, Cariati M, Brisinda G. Botulinum toxin versus other therapies for treatment of chronic anal fissure. Coloproctology. 2020; 42; 457-463.

4. Beaty JS, Shashidharan M. Anal Fissure. Clin Colon Rectal Surg. 2016; 29 (1): 30-37.

5. Medhi B, Rao RS, Prakash A, Prakash O, Kaman L, Pandhi P. Recent advances in the pharmacotherapy of chronic anal fissure: an update. Asian J Surg. 2008; 31 (3): 154-163.

6. Nelson RL, Thomas K, Morgan J, Jones A. Non surgical therapy for anal fissure. Cochrane Database Syst Rev. 2012; 2012 (2): CD003431.

7. Perry WB, Dykes SL, Buie WD, Rafferty JF; Standards Practice Task Force of the American Society of Colon and Rectal Surgeons. Practice parameters for the management of anal fissures (3rd revision). Dis Colon Rectum. 2010; 53 (8): 1110-1115.

8. Binder HJ. The expanding spectrum of clinical uses for botulinum toxin: healing of chronic anal fissures. Gastroenterology. 1999; 116 (1): 221-223.

9. Jones OM, Moore JA, Brading AF, Mortensen NJ. Botulinum toxin injection inhibits myogenic tone and sympathetic nerve function in the porcine internal anal sphincter. Colorectal Dis. 2003; 5 (6): 552-557.

10. Aguilar MDM, Moya P, Alcaide MJ, Fernández A, Gómez MA, Santos J et al. Results of the national survey on the treatment of chronic anal fissure in Spanish hospitals. Cir Esp. 2018; 96 (1): 18-24.

11. Abramowitz L, Bouchard D, Siproudhis L, Trompette M, Pillant H, Bord C et al. Psychometric properties of a questionnaire (HEMO-FISS-QoL) to evaluate the burden associated with haemorrhoidal disease and anal fissures. Colorectal Dis. 2019; 21 (1): 48-58.

12. Nelson RL. Anal fissure (chronic). BMJ Clin Evid. 2014; 2014: 0407.

13. Ebinger SM, Hardt J, Warschkow R, Schmied BM, Herold A, Post S et al. Operative and medical treatment of chronic anal fissures-a review and network meta-analysis of randomized controlled trials. J Gastroenterol. 2017; 52 (6): 663-676.

14. Sanei B, Mahmoodieh M, Masoudpour H. Comparison of topical glyceryl trinitrate with diltiazem ointment for treatment of chronic anal fissure. A randomized clinical trial. Ann Ital Chir. 2009; 80 (5): 379-383.

15. Telich-Tarriba JE, Martínez-Schulte A, Grajeda-Gómez A et al. Corrección de entropión en párpado inferior con toxina botulínica. Rev Mex Oftalmol. 2018; 92 (1): 39-42.

16. Jost WH, Schimrigk K. Use of botulinum toxin in anal fissure. Dis Colon Rectum. 1993; 36 (10): 974.

17. Boland PA, Kelly ME, Donlon NE, Bolger JC, Larkin JO, Mehigan BJ et al. Management options for chronic anal fissure: a systematic review of randomised controlled trials. Int J Colorectal Dis. 2020; 35 (10): 1807-1815.

18. Chen HL, Woo XB, Wang HS, Lin YJ, Luo HX, Chen YH et al. Botulinum toxin injection versus lateral internal sphincterotomy for chronic anal fissure: a meta-analysis of randomized control trials. Tech Coloproctol. 2014; 18 (8): 693-698.

19. Westfall TC, Westfall DP. Neurotransmission: the autonomic and somatic motor neuron systems. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman & Gillman's, The Pharmacological Basis of Therapeutics, 11th edition. New York: McGraw-Hill, 2006: 137-181.

20. Ravindran P, Chan DL, Ciampa C, George R, Punch G, White SI. High-dose versus low-dose botulinum toxin in anal fissure disease. Tech Coloproctol. 2017; 21 (10): 803-808.

21. Wald A, Bharucha A, Cosman B, Whitehead WE. ACG clinical guideline: Management of benign anorectal disorders. Am J Gastroenterol. 2014; 109 (8): 1141-1157.

22. Cross KL, Massey EJ, Fowler AL, Monson JR; ACPGBI. The management of anal fissure: ACPGBI position statement. Colorectal Dis. 2008; 10 Suppl 3: 1-7.

23. Kyriakakis R, Kelly-Schuette K, Hoedema R, Luchtefeld M, Ogilvie J. What predicts successful nonoperative management with botulinum toxin for anal fissure? Am J Surg. 2020; 219 (3): 442-444.

24. Bobkiewicz A, Francuzik W, Krokowicz L, Studniarek A, Ledwosinski W, Paszkowski J et al. Botulinum toxin injection for treatment of chronic anal fissure: is there any dose-dependent efficiency? A meta-analysis. World J Surg. 2016; 40 (12): 3064-3072.

25. Lin JX, Krishna S, Su'a B, Hill AG. Optimal dosing of botulinum toxin for treatment of chronic anal fissure: a systematic review and meta-analysis. Dis Colon Rectum. 2016;59 (9): 886-894.

26. Charúa GL, Fonseca ME, Guerra MLR et al. Tratamiento de la fisura anal crónica con toxina botulínica tipo A. Rev Gastroenterol Mex. 2007; 72 (1): 22-28.